Prevention of Diabetes: Why, How
and When
Website:
Click
here to view
Audience: This CME activity is designed to meet the educational
needs of cardiologists, endocrinologists, primary care physicians,
and other physicians caring for patients at risk for cardiovascular
disease.
Overview:
An estimated 20.8 million Americans (7% of the population)
have diabetes. The number with diagnosed diabetes is projected
to increase from 16.2 million (5.6%) to 48.3 million (12%)
in 2050—an increase of 198%. Diabetes prevalence may
increase even more if prevalence of obesity continues to
increase. In 2000, 4.4 million diabetic individuals aged
35 or older reported having cardiovascular disease (37.2%),
including 2.9 million with coronary heart disease and 1.1
million with stroke. Approximately 65% of individuals with
diabetes die of heart disease or stroke, and the risk for
heart disease death or stroke is 2–4 times higher
in individuals with diabetes than in individuals without
diabetes.
Objectives:
- Review the relationship between diabetes and cardiovascular
disease
- Discuss the efficacy of therapies that target adiposity
to prevent diabetes
- Describe the results of the recent DREAM trial using
pharmacological therapy to prevent diabetes
Credits Available:
Baylor College of Medicine designates this educational activity
for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.
Physicians should only claim credit commensurate with the
extent of their participation in the activity.
ACCME accredited providers may issue credit to both U.S.
and international physicians for any activity that has been
designated for AMA PRA Category 1 Credit(s)™ in accordance
with PRA requirements.
This activity has been evaluated and approved by the Continuing
Education Approval Program of the National Association of
Nurse Practitioners in Women’s Health for 2.0 contact
hours of continuing education credit including 2.0 pharmacology
contact hours.
Expires:
November 2007
Expanding the Therapeutic Options for Type
2 Diabetes Mellitus
Website:
Click
here to view
Audience:
This activity has been designed to meet the educational
needs of physicians, physician assistants, and nurse practitioners
involved in the management of patients with type 2 diabetes.
Overview:
Type 2 diabetes is characterized by insulin resistance,
progressive decline in pancreatic ß-cell function,
elevated levels of blood glucose, and abnormalities in glucagon
secretion and incretin response. Together, these abnormalities
lead to posprandial rises in blood glucose levels. The efficacy
of some medications may decrease as the disease progresses.
In addition, adverse effects of some medications include
hypoglycemia and weight gain. Newer diabetes treatment options
have emerged which address different mechanisms of action.
It is important for primary care providers to understand
the pathophysiology of diabetes and to keep abreast of new
treatment options and appropriate ways to incorporate new
modalities into existing therapeutic regimens.
Objectives:
After completing this activity, the participant should be
better able to:
- Describe pathophysiologic defects associated with type
2 diabetes mellitus.
- Summarize the importance of attaining glycemic goals
in type 2 diabetes patients.
- Describe the multiple sites of action of current diabetes
treatments.
- Discuss the clinical efficacy of newer agents and how
they can be incorporated into current therapeutic regimens.
Credits Available:
Physicians:
1.0 AMA PRA Category 1 Credit(s)TM
Physicians’ Assistants:
The American Academy of Physician Assistants accepts AMA
category 1 credit for the PRA from organizations accredited
by ACCME
Nurse Practitioners:
This program has been approved by The Nurse Practitioner
Association New York State (The NPA) for 1.2 contact hours.
Expires:
December 31, 2007
New Understandings in Treating Type
2 Diabetes and Cardiovascular Disease
Website:
Click
here to view
Audience:
This educational activity is designed for primary
care physicians, internists, cardiologists, endocrinologists,
and other healthcare professionals involved in the care
and treatment of patients with type 2 diabetes.
Overview:
Cardiovascular disease (CVD) is the leading cause of mortality
among patients with type 2 diabetes, accounting for approximately
80% of deaths. As healthcare professionals involved in treating
patients with type 2 diabetes, it is imperative that you
identify CVD risk factors and understand their implications
for your patients.
This activity will explore the pathophysiology of insulin
resistance, ß-cell dysfunction, and CVD in the patient
with type 2 diabetes. In addition, expert commentary will
be provided, illuminating the clinical implications of the
recently published PROactive study, which demonstrates that
a glucose-lowering therapy may prevent macrovascular events.
The PROactive study provides physicians and other healthcare
professionals with outcome data to help better manage cardiovascular
risk in patients with type 2 diabetes.
Objectives:
After participating in this CME activity, you will be better
able to:
- Identify markers of dyslipidemia, CVD, and inflammation
presented in patients with insulin resistance
and type 2 diabetes
- Characterize and evaluate the potential value of oral
antidiabetic agents in the treatment of patients
with type 2 diabetes and CVD
- Evaluate the medical evidence regarding the benefits
of insulin sensitizers on glycemic and non glycemic
targets in the patient with type 2 diabetes and dyslipidemia
- Assess the implications of the PROactive outcomes study
with respect to the pathophysiology of CVD
and the management of patients with type 2 diabetes
Credits Available:
Thomson Professional Postgraduate Services® designates
this educational activity for a maximum of 1.25 AMA PRA
Category 1 Credits™.
This activity has been reviewed and is acceptable for up
to 1 Prescribed credit by the American Academy of Family
Physicians.
Expires:
February 16, 2007
Modern Insulin Therapy in Type 2 Diabetes
Website:
Click
here to view
Audience:
This activity has been designed to meet the educational
needs of endocrinologists, primary care physicians and other
healthcare professionals involved in the care of patients
with type 2 diabetes.
Overview:
This CME program will discuss principles of flexible insulin
therapy and review new clinical trials that provide guidance
on initiation and titration of insulin analogs in patients
with type 2 diabetes who have not achieved glycemic goals
with oral therapy alone.
Objectives:
Upon completion of the activity, participants should be
better able to:
- Design treatment strategies for patients with type
2 diabetes who may benefit from initiation of insulin
therapy to improve glycemic control
- Describe different insulin treatment regimens (agent,
initial dose and titration schedule, intensification,
monitoring) and consider appropriate patient types for
such therapy
- Summarize the data from recent clinical trials of simple
and flexible insulin analog treatment strategies and discuss
how to translate the information from randomized trials
to clinical practice to improve patient care
Credits Available:
The University of Miami Leonard M. Miller School of Medicine
designates this educational activity for a maximum of 1
AMA PRA Category 1 Credit(s)™. Physicians should claim
only credit commensurate with the extent of their participation
in the activity.
